ONCSQ — OncoSec Medical Share Price
Last trade - 00:00- $0.00m
- -$1.39m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1990.88% | ||
| Return on Equity | -410.17% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jul | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec Medical System EP device (the OMS EP Device) and a DNA plasmid delivery and application method that enables transient expression of recombinant therapeutic molecules in cells. The OMS EP Device is designed to promote cellular uptake of plasmid DNA injected directly into solid tumors to allow subsequent expression of the encoded therapeutic protein. The OMS EP Device can be adapted to treat different tumor types and consists of an electrical pulse generator and a disposable applicator. Its lead product candidate, tavokinogene telseplasmid (TAVO), is a plasmid encoding human interleukin-12.
Directors
- Linda Shi CHM
- Robert Delaversano CAO (49)
- Joe Smith VBD
- Joon Kim DRC (55)
- Kevin Smith DRC (50)
- Chao Zhou DRC (32)
- James Demesa IND (63)
- Herbert Lyerly IND (62)
- Last Annual
- July 31st, 2022
- Last Interim
- January 31st, 2023
- Incorporated
- February 8th, 2008
- Public Since
- May 29th, 2015
- No. of Shareholders
- 42
- No. of Employees
- 40
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 5,962,652
- Address
- 820 Bear Tavern Road, EWING, 08628
- Web
- https://oncosec.com/
- Phone
- +1 8582107333
- Auditors
- Mayer Hoffman & McCann P.C.
Upcoming Events for ONCSQ
Similar to ONCSQ
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 22:29 UTC, shares in OncoSec Medical are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in OncoSec Medical last closed at $0.00 and the price had moved by -99.98% over the past 365 days. In terms of relative price strength the OncoSec Medical share price has underperformed the S&P500 Index by -99.98% over the past year.
The overall consensus recommendation for OncoSec Medical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
OncoSec Medical does not currently pay a dividend.
OncoSec Medical does not currently pay a dividend.
OncoSec Medical does not currently pay a dividend.
To buy shares in OncoSec Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in OncoSec Medical had a market capitalisation of $0.00m.
Here are the trading details for OncoSec Medical:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ONCSQ
Based on an overall assessment of its quality, value and momentum OncoSec Medical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OncoSec Medical. Over the past six months, its share price has underperformed the S&P500 Index by -9.44%.
As of the last closing price of $0.00, shares in OncoSec Medical were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The OncoSec Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
OncoSec Medical's management team is headed by:
- Linda Shi - CHM
- Robert Delaversano - CAO
- Joe Smith - VBD
- Joon Kim - DRC
- Kevin Smith - DRC
- Chao Zhou - DRC
- James Demesa - IND
- Herbert Lyerly - IND